Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: a propensity-matched study

Deok Gie Kim, Juhan Lee, Won Jun Seo, Jae Geun Lee, Beom Seok Kim, Myoung Soo Kim, Soon Il Kim, Yu Seun Kim, Kyu Ha Huh

Research output: Contribution to journalArticle

Abstract

Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. Rituximab is widely used for desensitization in ABO-incompatible or crossmatch-positive kidney transplantation (KT). Using a single-center KT database, we performed propensity-matched analysis to investigate the association between rituximab and posttransplant atherosclerotic cardiovascular disease (ASCVD). Among 1299 eligible patients, 239 given rituximab induction were matched with 401 controls in a 1:2 propensity score matching process. The cumulative rate of ASCVD during 8 years of follow-up was significantly lower in rituximab-treated patients, compared with matched controls (3.7% vs. 11.2%; P = 0.012). However, all-cause mortality did not differ by group (2.9% vs. 4%; P = 0.943). In multivariable Cox analysis, rituximab proved independently protective of ASCVD (hazard ratio = 0.34, 95% confidence interval: 0.14–0.83). The lower risk of ASCVD seen with rituximab induction reached significance only in patient subsets of diabetes mellitus, pretransplant dialysis, or older age (>50 years). Rituximab induction confers a lower risk of ASCVD during the posttransplant period. This atheroprotective effect appears particularly beneficial in patients whose risk of ASCVD is heightened.

Original languageEnglish
Article number16475
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 2019 Dec 1

Fingerprint

Kidney Transplantation
Cardiovascular Diseases
Propensity Score
Rituximab
Dialysis
Atherosclerosis
Diabetes Mellitus
B-Lymphocytes
Databases
Confidence Intervals
Mortality

All Science Journal Classification (ASJC) codes

  • General

Cite this

Kim, Deok Gie ; Lee, Juhan ; Seo, Won Jun ; Lee, Jae Geun ; Kim, Beom Seok ; Kim, Myoung Soo ; Kim, Soon Il ; Kim, Yu Seun ; Huh, Kyu Ha. / Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation : a propensity-matched study. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{a6a9b0f85c464c6d9e1a72560c100c3e,
title = "Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation: a propensity-matched study",
abstract = "Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. Rituximab is widely used for desensitization in ABO-incompatible or crossmatch-positive kidney transplantation (KT). Using a single-center KT database, we performed propensity-matched analysis to investigate the association between rituximab and posttransplant atherosclerotic cardiovascular disease (ASCVD). Among 1299 eligible patients, 239 given rituximab induction were matched with 401 controls in a 1:2 propensity score matching process. The cumulative rate of ASCVD during 8 years of follow-up was significantly lower in rituximab-treated patients, compared with matched controls (3.7{\%} vs. 11.2{\%}; P = 0.012). However, all-cause mortality did not differ by group (2.9{\%} vs. 4{\%}; P = 0.943). In multivariable Cox analysis, rituximab proved independently protective of ASCVD (hazard ratio = 0.34, 95{\%} confidence interval: 0.14–0.83). The lower risk of ASCVD seen with rituximab induction reached significance only in patient subsets of diabetes mellitus, pretransplant dialysis, or older age (>50 years). Rituximab induction confers a lower risk of ASCVD during the posttransplant period. This atheroprotective effect appears particularly beneficial in patients whose risk of ASCVD is heightened.",
author = "Kim, {Deok Gie} and Juhan Lee and Seo, {Won Jun} and Lee, {Jae Geun} and Kim, {Beom Seok} and Kim, {Myoung Soo} and Kim, {Soon Il} and Kim, {Yu Seun} and Huh, {Kyu Ha}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-52942-8",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation : a propensity-matched study. / Kim, Deok Gie; Lee, Juhan; Seo, Won Jun; Lee, Jae Geun; Kim, Beom Seok; Kim, Myoung Soo; Kim, Soon Il; Kim, Yu Seun; Huh, Kyu Ha.

In: Scientific reports, Vol. 9, No. 1, 16475, 01.12.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rituximab protects against development of atherosclerotic cardiovascular disease after kidney transplantation

T2 - a propensity-matched study

AU - Kim, Deok Gie

AU - Lee, Juhan

AU - Seo, Won Jun

AU - Lee, Jae Geun

AU - Kim, Beom Seok

AU - Kim, Myoung Soo

AU - Kim, Soon Il

AU - Kim, Yu Seun

AU - Huh, Kyu Ha

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. Rituximab is widely used for desensitization in ABO-incompatible or crossmatch-positive kidney transplantation (KT). Using a single-center KT database, we performed propensity-matched analysis to investigate the association between rituximab and posttransplant atherosclerotic cardiovascular disease (ASCVD). Among 1299 eligible patients, 239 given rituximab induction were matched with 401 controls in a 1:2 propensity score matching process. The cumulative rate of ASCVD during 8 years of follow-up was significantly lower in rituximab-treated patients, compared with matched controls (3.7% vs. 11.2%; P = 0.012). However, all-cause mortality did not differ by group (2.9% vs. 4%; P = 0.943). In multivariable Cox analysis, rituximab proved independently protective of ASCVD (hazard ratio = 0.34, 95% confidence interval: 0.14–0.83). The lower risk of ASCVD seen with rituximab induction reached significance only in patient subsets of diabetes mellitus, pretransplant dialysis, or older age (>50 years). Rituximab induction confers a lower risk of ASCVD during the posttransplant period. This atheroprotective effect appears particularly beneficial in patients whose risk of ASCVD is heightened.

AB - Recent studies have implicated B cells in atherosclerosis and have verified the atheroprotective effect of rituximab. Rituximab is widely used for desensitization in ABO-incompatible or crossmatch-positive kidney transplantation (KT). Using a single-center KT database, we performed propensity-matched analysis to investigate the association between rituximab and posttransplant atherosclerotic cardiovascular disease (ASCVD). Among 1299 eligible patients, 239 given rituximab induction were matched with 401 controls in a 1:2 propensity score matching process. The cumulative rate of ASCVD during 8 years of follow-up was significantly lower in rituximab-treated patients, compared with matched controls (3.7% vs. 11.2%; P = 0.012). However, all-cause mortality did not differ by group (2.9% vs. 4%; P = 0.943). In multivariable Cox analysis, rituximab proved independently protective of ASCVD (hazard ratio = 0.34, 95% confidence interval: 0.14–0.83). The lower risk of ASCVD seen with rituximab induction reached significance only in patient subsets of diabetes mellitus, pretransplant dialysis, or older age (>50 years). Rituximab induction confers a lower risk of ASCVD during the posttransplant period. This atheroprotective effect appears particularly beneficial in patients whose risk of ASCVD is heightened.

UR - http://www.scopus.com/inward/record.url?scp=85074841248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074841248&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-52942-8

DO - 10.1038/s41598-019-52942-8

M3 - Article

C2 - 31712593

AN - SCOPUS:85074841248

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16475

ER -